Quince Therapeutics (QNCX) Accounts Payables (2018 - 2026)

Quince Therapeutics has reported Accounts Payables for 9 years, with the latest figure at $4.6 million in Q2 2026.

• On a quarterly basis, Accounts Payables rose 163.56% year-over-year to $4.6 million in Q2 2026; TTM through Jun 2026 was $4.6 million, a 163.56% increase from a year earlier, with the FY2025 full-year figure at $2.2 million, down 23.42% from the prior year.
• Accounts Payables was $4.6 million for Q2 2026 at Quince Therapeutics, down from $5.4 million in the prior quarter.
• The five-year high for Accounts Payables was $5.4 million in Q1 2026, with the low at $353000.0 in Q2 2023.
• Average Accounts Payables over 5 years is $2.3 million, with a median of $2.1 million recorded in 2023.
• The sharpest annual moves came in 2022 and 2024: Accounts Payables sank 88.39% in 2022, then jumped 581.3% in 2024.
• Over 5 years, Accounts Payables stood at $570000.0 in 2022, then surged by 256.67% to $2.0 million in 2023, then jumped by 42.79% to $2.9 million in 2024, then slipped by 23.42% to $2.2 million in 2025, then soared by 108.55% to $4.6 million in 2026.
• The last three Accounts Payables figures came in at $4.6 million (Q2 2026), $5.4 million (Q1 2026), and $2.2 million (Q4 2025), per Business Quant data.